Novartis Reports Phase 2 Data for Lisocabtagene maraleucel in Multiple myeloma

Novartis today announced Phase 2 results for lisocabtagene maraleucel in patients with multiple myeloma. The study demonstrated that lisocabtagene maraleucel reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of multiple myeloma and support the continued development of lisocabtagene maraleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.